Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO-CKD trial of henagliflozin in type 2 diabetes with chronic kidney disease
ChiCTR2300076565Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change in urinary albumin-to-creatinine ratio from baseline. Started Oct 2023; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2300076565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076565.